News

Science 37® and Signant Health Partner to Expand Access to CNS Research with Decentralized Clinical Trials

Science 37 and Signant Health have announced a partnership to strengthen capabilities for decentralized or virtual CNS clinical research. By bringing research to patients at home, the partnership will ease the participation burden typical of a traditional study, and with CNS as the second largest therapeutic area in clinical research, the partnership also will enable crucial telepsychiatry services for the growing therapeutic market.

Continue

Science 37® Supports DCRI’s First Direct-to-Family Study for Pediatric Lupus

Science 37 is excited to be part of the first-of-its-kind direct-to-family study with the Duke Clinical Research Institute (DCRI) for decentralized research in pediatric lupus. The iPERSONAL (Individual Patient Exposure and Response in Pediatric Lupus) study will help determine the most effective dose of hydroxychloroquine for children and teens with lupus as well as whether a digital pill bottle aids medication adherence. As the world continues to adapt to the global COVID-19 pandemic, the study…

Continue

Science 37® Integrates Electronic Health Records into Its Decentralized Clinical Trial Technology Platform

Patients using Science 37’s technology platform can now connect their health record directly, in real time—eliminating paper documentation and streamlining information sharing.   LOS ANGELES, September 10, 2020 — Science 37, the industry leader in decentralized clinical trials, today launched an electronic health record (EHR) integration feature for more than 10,000 health facilities and 280 million U.S. patients. With this connection, patients using Science 37’s best-in-class technology platform can easily authorize and share their health record…

Continue

John Hubbard, Ph.D., Joins Science 37® Board of Directors

LOS ANGELES, September 2, 2020 — Science 37, the industry leader in decentralized clinical trials, today announced the appointment of industry veteran John Hubbard, Ph.D., FCP to its Board of Directors. Dr. Hubbard brings more than three decades of experience across multiple senior executive roles with the industry’s foremost organizations. Most recently, he was President and Chief Executive Officer at Bioclinica, a leading medical imaging and technology-enabled clinical services provider. During Dr. Hubbard’s tenure, the…

Continue

ERT and Science 37® Partner to Deliver High-Quality Data during Virtual Trials

Technology partnership enables trial sponsors to improve imaging, respiratory, and cardiac safety data quality while reducing patient burden and risk.   PHILADELPHIA & LOS ANGELES, August 25, 2020 —  ERT, the global leader in clinical endpoint data collection and Science 37, the leader in decentralized clinical trials, today announced a partnership enabling ERT’s Cardiac Safety, Respiratory, and Imaging solutions to be incorporated into the Science 37 virtual, or decentralized clinical trial offering. The combined solution…

Continue

Science 37® Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market

In a significantly oversubscribed offering, Science 37 attracted capital to support its rapid growth, expand its technology platform, and accelerate global expansion.      LOS ANGELES, August 20, 2020 — Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round. Existing investors Lux Capital, Redmile Group, and PPD, Inc. (Nasdaq: PPD) led the round, and are joined by existing investors Novartis, Amgen, Sanofi Ventures, GV, and Glynn…

Continue

Science 37® Named to 2020 CB Insights Digital Health 150—List of Most Innovative Digital Health Start-Ups

Science 37, the industry leader in decentralized clinical trials, has been named to the Digital Health 150, CB Insights’ annual ranking of the most promising digital health companies in the world.

Continue

Science 37® and Advarra Detail Methods for Research Continuity

A new whitepaper from Science 37 and Advarra explores how research is continuing in the COVID-19 era.   Although many nations appear to have turned the tide in the current global pandemic, the effects of COVID-19 will continue to reverberate for months and years to come. As we continue in this era, how has the pandemic changed clinical trials? What do institutional review boards (IRBs) say about reporting protocol changes and ensuring patient safety? Fresh…

Continue

Science 37® Furthers Global Expansion and Decentralized Trial Leadership

Science 37 adds to its industry-leading virtual trial capabilities in Europe, South America, and Asia-Pacific.    LOS ANGELES, July 28, 2020 — Science 37, the industry leader in decentralized clinical trials, today announced a series of global investments, including an expanded European, Latin American and Asian nurse and investigator network, staffing in key European countries, and an operational center of excellence in Slovakia. “By strengthening our global presence, we’re enabling our sponsors to execute more decentralized…

Continue